Alyeska Investment Group’s Structure Therapeutics GPCR Stock Holding History

Alyeska Investment Group’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-115,000	Closed	-$8M	–	669
2025 Q4	$8M	Sell	115,000 -129,848	-53%	-$5.3M	0.02%	417
2025 Q3	$6.86M	Buy	+244,848	New	+$4.88M	0.02%	424
2024 Q4	–	Sell	-7,660	Closed	-$336K	–	597
2024 Q3	$336K	Sell	7,660 -699,730	-99%	-$27.1M	﹤0.01%	496
2024 Q2	$27.8M	Sell	707,390 -593,596	-46%	-$24.4M	0.16%	176
2024 Q1	$55.8M	Buy	1,300,986 +1,122,309	+628%	+$47.3M	0.34%	100
2023 Q4	$7.28M	Buy	+178,677	New	+$10.2M	0.05%	283

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Alyeska Investment Group's GPCR Position: Q1 2026 in Review

Alyeska Investment Group sold out of Structure Therapeutics (GPCR) in Q1 2026, closing a stake of 115,000 shares — an estimated $8M sold.

Alyeska Investment Group first reported a position in GPCR in Q4 2023 and held it in 6 quarters. The position peaked at $55.8M in Q1 2024. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Alyeska Investment Group reported no remaining Structure Therapeutics position as of Q1 2026 after selling out during the quarter.
Alyeska Investment Group sold 115,000 Structure Therapeutics shares in Q1 2026, an estimated $8M.
Alyeska Investment Group first reported a position in Structure Therapeutics in Q4 2023 and held it in 6 quarters.
Alyeska Investment Group's Structure Therapeutics position peaked at $55.8M in Q1 2024.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.